BR112015026019A2 - métodos e composições de tratamento de doenças autoimunes - Google Patents
métodos e composições de tratamento de doenças autoimunesInfo
- Publication number
- BR112015026019A2 BR112015026019A2 BR112015026019A BR112015026019A BR112015026019A2 BR 112015026019 A2 BR112015026019 A2 BR 112015026019A2 BR 112015026019 A BR112015026019 A BR 112015026019A BR 112015026019 A BR112015026019 A BR 112015026019A BR 112015026019 A2 BR112015026019 A2 BR 112015026019A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- autoimmune diseases
- treating autoimmune
- immunosuppressive
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 3
- 230000001506 immunosuppresive effect Effects 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 108010047482 ectoATPase Proteins 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000003614 tolerogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
Abstract
resumo da patente de invenã§ã£o para: âmãtodos e composiãães de tratamento de doenãas autoimunesâ. modalidades de vã¡rios aspectos descritos aqui sã£o direcionados a mã©todos e composiã§ãµes para produã§ã£o de cã©lula dendrãtica imunossupressora ou tolerogãªnica. em particular, uma cã©lula dentrãtica imunossupressora pode ser produzida pelo contato de uma cã©lula dendrãtica com um agente que estimula a sinalizaã§ã£o de eixo il-27/ectonucleotidase cd39. em algumas modalidades, os mã©todos e/ou composiã§ãµes descritas aqui podem ser usadas para o tratamento de uma doenã§a ou desordem autoimune, por exemplo, mas nã£o limitada a esclerose mãºltipla (ms) e diabetes tipo 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361853745P | 2013-04-11 | 2013-04-11 | |
PCT/US2014/033872 WO2014169255A1 (en) | 2013-04-11 | 2014-04-11 | Methods and compositions of treating autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015026019A2 true BR112015026019A2 (pt) | 2017-07-25 |
Family
ID=51690049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015026019A BR112015026019A2 (pt) | 2013-04-11 | 2014-04-11 | métodos e composições de tratamento de doenças autoimunes |
Country Status (6)
Country | Link |
---|---|
US (2) | US10426794B2 (pt) |
EP (1) | EP2983791A4 (pt) |
CN (1) | CN105307725B (pt) |
BR (1) | BR112015026019A2 (pt) |
CA (1) | CA2918196A1 (pt) |
WO (1) | WO2014169255A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
JP6744227B2 (ja) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 糖標的化治療剤 |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
WO2017042814A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Use of perforin positive immature dendritic cells in disease treatment |
WO2017143346A1 (en) * | 2016-02-18 | 2017-08-24 | Cour Pharmaceuticals Development Company, Inc. | Process for the preparation of tolerizing immune-modulating particles |
JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗pd-l1およびil-2サイトカイン |
CA3039068A1 (en) * | 2016-10-07 | 2018-04-12 | Secarna Pharmaceuticals Gmbh & Co. Kg | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39 |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
JP2021526795A (ja) * | 2018-06-05 | 2021-10-11 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 筋特異的キナーゼキメラ自己受容体細胞の組成物および方法 |
WO2020237305A1 (en) * | 2019-05-27 | 2020-12-03 | Baker Heart and Diabetes Institute | Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases |
EP4359084A1 (en) * | 2021-06-22 | 2024-05-01 | The Trustees of Columbia University in the City of New York | Novel mrna vaccine for autoimmunity |
CN114931633A (zh) * | 2022-06-10 | 2022-08-23 | 苏州尔生生物医药有限公司 | 一种来源于预激活抗原提呈细胞的自身免疫疾病疫苗的制备方法及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60336930D1 (de) * | 2002-12-31 | 2011-06-09 | Schering Corp | IL-27 et IL-2 pour le traitement du cancer |
CA2591587A1 (en) * | 2004-12-16 | 2006-06-22 | Genentech, Inc. | Methods for treating autoimmune disorders |
AU2007288334A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
EP2091555A1 (en) * | 2006-12-07 | 2009-08-26 | Schering Corporation | Use of il-27 agonists to reduce immune mediated abortion |
US9295736B2 (en) | 2007-09-24 | 2016-03-29 | Bar Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
EP2217250A4 (en) * | 2007-11-09 | 2011-01-05 | California Inst Of Techn | IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS |
KR101361416B1 (ko) * | 2008-10-08 | 2014-02-21 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
CA2747951A1 (en) * | 2008-12-22 | 2010-07-01 | Kingston Mills | Compounds and methods for the treatment of autoimmune and inflammatory disease |
AU2010234743A1 (en) | 2009-03-31 | 2011-10-20 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
AU2011268146A1 (en) * | 2010-06-17 | 2013-01-10 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
-
2014
- 2014-04-11 WO PCT/US2014/033872 patent/WO2014169255A1/en active Application Filing
- 2014-04-11 EP EP14782473.4A patent/EP2983791A4/en not_active Withdrawn
- 2014-04-11 CN CN201480033535.7A patent/CN105307725B/zh not_active Expired - Fee Related
- 2014-04-11 CA CA2918196A patent/CA2918196A1/en not_active Abandoned
- 2014-04-11 US US14/783,679 patent/US10426794B2/en active Active
- 2014-04-11 BR BR112015026019A patent/BR112015026019A2/pt not_active Application Discontinuation
-
2019
- 2019-09-30 US US16/588,234 patent/US20200069731A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014169255A1 (en) | 2014-10-16 |
EP2983791A1 (en) | 2016-02-17 |
US20160058792A1 (en) | 2016-03-03 |
EP2983791A4 (en) | 2016-11-09 |
US20200069731A1 (en) | 2020-03-05 |
US10426794B2 (en) | 2019-10-01 |
CN105307725A (zh) | 2016-02-03 |
CN105307725B (zh) | 2020-06-16 |
CA2918196A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015026019A2 (pt) | métodos e composições de tratamento de doenças autoimunes | |
BR112016003053A2 (pt) | micropartículas de células tronco e mirna | |
BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
BR112015019794A2 (pt) | composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto | |
CY1122189T1 (el) | Ιονικες υδατικες συνθεσεις | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
CL2015002522A1 (es) | Composiciones y métodos para activar "estimulador de interferon gene" - señalización dependientes. | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
EA201591839A1 (ru) | Терапевтические пептиды | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
EA201492055A1 (ru) | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ | |
BR112015015870A2 (pt) | composição farmacêutica | |
BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
BR112014030534A2 (pt) | composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada | |
BR112018076639A2 (pt) | quimioterapias de combinação | |
BR112015022825A2 (pt) | métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos | |
BR112014030279A2 (pt) | métodos para tratamento de neutropenia usando agonistas retinóide | |
EA201592073A1 (ru) | Фармацевтические композиции, содержащие коллаген и гиалуронат натрия | |
JOP20190241B1 (ar) | مستحضرات رذاذ إبينيفرين |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |